Geetanjali Sharma, Chelin Hu, Daniela I Staquicini, Jonathan L Brigman, Meilian Liu, Franck Mauvais-Jarvis, Renata Pasqualini, Wadih Arap, Jeffrey B Arterburn, Helen J Hathaway, Eric R Prossnitz
Human obesity has become a global health epidemic, with few safe and effective pharmacological therapies currently available. The systemic loss of ovarian estradiol (E2) in women after menopause greatly increases the risk of obesity and metabolic dysfunction, revealing the critical role of E2 in this setting. The salutary effects of E2 are traditionally attributed to the classical estrogen receptors ERα and ERβ, with the contribution of the G protein-coupled estrogen receptor (GPER) still largely unknown...
January 29, 2020: Science Translational Medicine